I have the report as a PDF with the chromatogram on page two, so I can quote specifics.
I can do the algebra. I am not confident about the conversion factors.
If there is a standard way to lay this out, I would rather learn that than invent one.
What is the general form of this calculation?
For 39 residues that is 38 couplings, and the crude arithmetic sets the ceiling before purification starts. At 99.5 per cent average coupling efficiency, 0.995^38 leaves 82.7 per cent full-length in the crude; at 99 per cent it leaves 68.3 per cent. Half a percentage point per step costs 14.4 points over 38 of them, which is the whole reason solid-phase chemistry obsesses over coupling and capping. Purification then buys most of it back, so a finished 39-mer in the high nineties is routine and above about 98 per cent you are fighting the separation rather than the synthesis. Anyone quoting 99.9 per cent on a chain this length should be asked for the chromatogram and the integration limits before anything else.
It helps to be literal here: the method matters more than the vial, which is why specifying a method buys you far more than changing suppliers does.
Gradient slope controls resolution, and gentler slopes resolve co-eluting impurities into separate peaks — so the better method reports the worse purity number.
The part that matters: mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.
Inter-laboratory studies on identical peptide material routinely find half-a-per-cent to a full-per-cent spreads in reported purity on the same sample.
Worth noting that method standardisation is poor in the research-grade space compared to pharmaceutical work, so identical-looking methods can produce different results.
The practical summary: ask for the chromatogram and the method, and ignore the headline number until you have both.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsStated carefully, identity and purity are orthogonal, and a high purity says almost nothing about whether the peak is actually what you think it is.
Tailing factor measures peak shape, and a badly tailing peak spreads into the region where small impurities live, forcing tangent-skim integration that assigns tail area to the main peak.
Specifically, retention time is sequence-specific and method-specific, so comparing your result to a supplier value using a different method is meaningless without method documentation.
Published side-by-side method comparisons show that a two-point difference in purity on the same vial is easily explained by method choice alone.
I would be careful about over-reading a single measurement — treat it as a data point, not as ground truth.
If you are ranking vendors, specify a method and have all samples tested at the same place.
Start from what the detector sees, because that tells you what the number means.
Sample solvent strength affects peak shape — if you inject in strong solvent on a gradient starting in weak solvent, the solvent peak can distort your main peak or create a false shoulder.
More usefully, mass on column affects detector linearity and peak overlap — overloading broadens peaks and hides neighbours, while underloading improves resolution but loses sensitivity.
The caveat is that purity without identity is only half an answer — a high purity does not mean the peak is actually what you think it is.
Compare purity within a single laboratory on the same method, never across laboratories.
Read the chromatogram before you read the number, because the number without the trace is not a measurement, it is a claim.
Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.
The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.
If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.
The short answer is that two competent laboratories on identical material will disagree, and the disagreement is almost always explainable by method differences.
Temperature affects the dynamics of molecular conformation, and if a peptide has proline residues that interconvert on the chromatographic timescale, the peak will split or shoulder at low temperature and collapse at high temperature.
Proline conformer interconversion kinetics are well-characterised and the half-life is of the same order as the chromatographic peak width at room temperature.
In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.